Summit Corporation plc
("Summit plc" or "the Company")
NOTICE OF ANNUAL GENERAL MEETING
Oxford, UK, 18 June 2008 - Summit Corporation plc (AIM: SUMM), a
leading UK biotechnology company, announces that its Annual Report
and Accounts for the year ended 31 January 2008 ("Annual Report")
together with the Notice of Annual General Meeting ("AGM") and the
Proxy Form have been posted to shareholders.
For the information of investors and shareholders alike, copies of
the Annual Report will be available for at least one month, free of
charge, at the Company's offices being 91 Milton Park, Abingdon,
Oxfordshire OX14 4RY. Electronic copies are available on the
Company's website, www.summitplc.com.
The AGM of Summit plc will be held at the offices of Citigate Dewe
Rogerson, 3 London Wall Buildings, London Wall, London, EC2M 5SY, on
Wednesday, 9 July 2008 at 09.30hrs.
- ENDS -
For more information, please contact:
Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951; +44 (0)7825 313476
Citigate Dewe Rogerson
Mark Swallow, PhD / David Dible / Sylvie Berrebi / Emma Palmer
Tel: +44 (0)207 638 9571
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600
About Summit plc
Summit plc is a leading UK biotechnology company with a broad
preclinical and clinical pipeline, two world-leading technology
platforms and an innovative business model that is expected to
generate sustainable value for investors.
Summit is developing multiple drug programmes that target unmet
medical needs from which it intends to generate value by
out-licensing attractive late preclinical or early clinical stage
programmes in return for upfront, milestone and royalty payments.
Summit uses its scientific expertise to target orphan diseases,
neuro-disorders and infectious diseases.
Underpinning Summit's drug pipeline are two innovative technology
platforms: carbohydrate chemistry and zebrafish biology. These
platforms support existing programmes and also will be the source of
future programmes to replenish Summit's drug pipeline. These
platform technologies also form the basis of the Company's profitable
The company listed on the alternative investment market (AIM) of the
London Stock Exchange in October 2004 - symbol: SUMM. Further
information about the company is available at www.summitplc.com.
---END OF MESSAGE---